01 Rising Geriatric PopulationThe global population is undergoing a dramatic demographic shift, with a substantial increase in the proportion of older adults. This demographic trend, known as population aging, is fueled by variables such as rising life expectancy and diminishing birth rates. The aging population has far-reaching consequences for healthcare, including an increased prevalence of chronic and complex medical disorders. As people age, they are more likely to experience various health concerns simultaneously, necessitating advanced diagnostic methods like esoteric testing to manage their health properly.Additionally, chronic problems such as cardiovascular disease, neurological disorders (e.g., Alzheimer's disease), and certain types of cancer are more prevalent in the elderly. It is projected that 70% of adults over the age of 70 will have CVD, with more than two-thirds having noncardiovascular comorbidities. In a large national study of Medicare members aged 65 and older, CVD was commonly associated with diabetes (37%-47%), anemia (39%-51%), and arthritis (41%-46%). Multimorbidity, or having two or more chronic illnesses simultaneously, is common among the elderly. According to one study, the prevalence of multimorbidity among older persons ranged from 4.8% to 93.1%. Another study discovered that multimorbidity prevalence rises with age, from 48.31% in those 45 and older to 73.86% in those over 75.Moreover, esoteric testing, such as genomic profiling, can help discover genetic predispositions and adapt treatment approaches for age-related illnesses. The growing aging population offers problems to global healthcare systems due to increased demand for medical services and diagnostic tests. As healthcare systems adjust to the needs of an aging population, integrating precision medicine and modern diagnostic tools becomes critical to improving the health outcomes and quality of life for older people. Esoteric testing, which allows for thorough molecular and genetic analysis, is essential to offering specialized and effective healthcare solutions for the aging population.
01 Limited Reimbursement PoliciesThe reimbursement environment influences the uptake of medical procedures, particularly esoteric testing. Esoteric diagnostics may require specialized technology and processes, which may be more expensive than regular diagnostic testing. The limited coverage or payment rules for specific tests can be a substantial barrier for patients and healthcare providers. Esoteric tests encompass a wide range of specialist diagnostic procedures, and the absence of defined reimbursement codes for many of these tests makes it difficult to establish consistent payment rules. The rapid expansion of esoteric testing technology can exceed the development of reimbursement policies, resulting in delays in coverage decisions. Furthermore, the complexities of esoteric test results may make it difficult for legislators to create clear and consistent reimbursement arrangements.Furthermore, according to research by the American Clinical Laboratory Association (ACLA), reimbursement rates for genetic tests have been under pressure in recent years, threatening the financial viability of laboratories that provide these tests. This trend has prompted worries among healthcare practitioners and diagnostic laboratories regarding the viability of offering esoteric genetic testing services. Globally, comparable issues exist regarding funding for esoteric testing, with healthcare systems balancing access to novel diagnostics and managing healthcare expenditures.
01 Emerging Applications in OncologyOncology offers a dynamic environment for esoteric testing, with a growing emphasis on customized treatment approaches and the development of targeted treatments. In 2023, there are expected to be 20 million new cancer diagnoses and 10 million fatalities worldwide. In the United States, 1,958,310 new cases are projected in 2023, with 609,820 deaths from cancer. Esoteric tests are critical in cancer diagnosis, prognosis, and personalized treatment options, contributing to advances in precision oncology.Additionally, liquid biopsy is an unusual testing procedure that involves the detection of circulating tumor DNA (ctDNA) or other biomarkers in physiological fluids. It provides a non-invasive method of detecting and monitoring cancer, enabling early detection and treatment monitoring. The use of liquid biopsy to detect genetic abnormalities related to lung cancer. Studies have shown that it can discover actionable mutations, guide targeted medicines, and track therapy response.Furthermore, esoteric procedures such as next-generation sequencing (NGS) and molecular profiling reveal extensive information regarding tumor genetics. This information is critical for determining which mutations and changes can be targeted with precision medicines. Genomic profiling in breast cancer involves testing for HER2/neu, estrogen receptor (ER), and progesterone receptor (PR) status to guide the selection of targeted therapy, such as Herceptin or hormone therapies. The Global Cancer Genomics Consortium (GCGC) is actively involved in collaborative efforts to standardize and improve genomic testing in oncology. This effort intends to strengthen the global implementation of genetic testing, promoting precision medicine in cancer treatment.
January 2026 Labcorp divested select assets of its early development medical device testing business to NAMSA, enabling the company to sharpen its focus on core preclinical drug development and specialized laboratory testing services while expanding NAMSA's testing capabilities.
November 2025 Abbott entered into a definitive agreement to acquire Exact Sciences in a transaction valued at approximately USD 23 billion, strengthening its diagnostics portfolio with advanced molecular and cancer screening technologies widely used in specialized laboratory testing.
July 2025 Waters Corporation and Becton, Dickinson and Company (BD) announced a Reverse Morris Trust merger combining Waters with BD's Biosciences & Diagnostic Solutions business. The transaction expands capabilities across specialty diagnostics, bioanalytical testing, and laboratory technologies.
May 2025 Function Health acquired Ezra, integrating AI-powered full-body MRI screening with its advanced laboratory testing platform to expand preventive and precision diagnostic services.